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Evaluation ofToxicity following Electrically Mediated Interleukin-12
Gene Delivery in a B16MouseMelanomaModel
LoreeHeller,1,2 KathleenMerkler,2 Jeffrey Westover,2 Yolmari Cruz,2 Domenico Coppola,3 KaaronBenson,3
Adil Daud,3,4 and Richard Heller1,2,4
Abstract Purpose: Interleukin-12 (IL-12) has potential as an immunotherapeutic agent for the treatment of
cancer but is unfortunately associated with toxicity. Delivery of a plasmid encoding IL-12 with
electroporation induces an antitumor effect in the B16 mouse melanoma model without serious
side effects. To translate this observation to the clinic, an evaluation of toxicity was done in the
mouse model.
Experimental Design:Weight change, tumor response, blood chemistry and hematology val-
ues, and serum IL-12 levels were evaluated. Multiple tissues were analyzed histopathologically.
Results: A pronounced reduction in tumor volume, including a large percentage of complete
regressions, was observed after electrically mediated gene therapy. No significant increases
in serum IL-12 levels were detected. Tumor-bearing mice showed an increased number of
atypical hematology values when compared with normal naive controls. Statistically significant
differences in chemistry and hematology values were observed sporadically in most of the stan-
dard chemistry and hematology categories in all groups. The only histopathologic abnormality
specific to the animals receiving both plasmid and electroporation was inflammation associated
with the kidney at the last time point.
Conclusions: In general, mice that received both plasmid and electroporation showed the least
abnormal histopathologic findings andwere found to be in the best health, reflecting the reduced
burden of disease. No significant toxic effects due to the IL-12 gene therapy were observed.
Interleukin-12 (IL-12) is a versatile cytokine and has great
potential as an immunotherapeutic agent for the treatment of
cancer. Recombinant protein therapy has had some success,
but unfortunately it has been associated with toxicity. When
given systemically in a phase I clinical trial, recombinant IL-12
induced multiple serious adverse effects, including renal and
systemic toxicity (1, 2). High-dose levels were linked to
temporary immune suppression, which would be unfavorable
for effective immunotherapy. A successful anticancer treatment
protocol should be one that initiates an extensive, rapid
immune response without inducing these toxic side effects.
Delivery of IL-12 in the form of gene therapy for melanomas
has shown some success without serious adverse side effects
(3, 4) and has reached clinical trials (5).
Electroporation is a physical method that facilitates uptake of
molecules by increasing the permeability of the cell membrane.
In vivo electroporation has been used to deliver chemothera-
peutic agents, such as bleomycin, in both animal studies and
clinical trials (6–14). The same rationale for using in vivo
electroporation to deliver chemotherapeutic agents is valid for
the delivery of larger molecules, such as plasmid DNA.
Electrically mediated delivery of several cytokine cDNAs has
been shown in the B16 melanoma model (15–22).
Many of the preclinical IL-12 studies examining delivery of
DNA encoding the IL-12 cDNAs as a single treatment for
melanoma have been conducted in the poorly immunogenic
and metastatic B16 murine melanoma model. Significant
inhibition of tumor growth was observed after adenoviral
delivery (17) as well as delivery mediated by Semliki Forest
virus (23). Plasmids encoding the cDNAs have been delivered
therapeutically in this model using the gene gun (3), electro-
poration (17, 18, 21, 22), injection alone (24), or a chemical
carrier (25). The majority of studies have shown inhibition of
tumor growth or limited tumor regression. IL-12 gene therapy
has also resulted in the regression of established tumors and
protection against lung metastasis following challenge in this
model (22, 26, 27).
Complete regression of established B16-F10 melanomas has
only been observed after DNA delivery by in vivo electroporation
(21, 22) or when electroporation was used to deliver IL-12
plasmid in combination with bleomycin (28). Intratumor
injection of a plasmid encoding IL-12 followed by electro-
poration results in an 80% cure rate of established B16-F10
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tumors in mice (22). Twelve of 12 cured mice were resistant to
subsequent challenge with B16-F10 cells. In addition, i.m.
injection of plasmid encoding IL-12 followed by electroporation
significantly reduced the formation of lung colonies following
i.v. injection of B16-F10 cells. Electrically mediated IL-12
plasmid delivery resulted in both a therapeutic response to
existing tumors and a prophylactic effect against metastases. To
translate this to the clinic, the following study was done to fully
characterize the potential toxicity following treatment by
intratumor in vivo electroporation of IL-12 plasmid DNA.
Materials andMethods
This study was approved by the University of South Florida
Institutional Animal Care and Use Committee (Tampa, FL). This
committee follows USPHS Policy on Humane Care and Use of
Laboratory Animals (www.grants.nih.gov/grants/olaw/olaw.htm#pol).
Cells lines and propagation. B16-F10 murine melanoma cells (CRL
6475, American Type Culture Collection, Rockville, MD) were
maintained as monolayers in 90% McCoy’s medium with 10% fetal
bovine serum and 1% gentamicin. The cells were removed from flasks
using trypsin-EDTA (0.05% trypsin-0.53 mmol/L EDTA; Mediatech),
collected by centrifugation, and washed, and cell viability was assessed
by trypan blue exclusion dye method. Cells with a viability of >90%
were resuspended in sterile PBS at 2  107/mL for injection.
Tumor induction. Tumors were established in the flank of 6- to
7-week-old male and female C57Bl/6 mice (National Cancer Institute,
NIH, Bethesda, Maryland) by the s.c. injection of 0.05 mL (106) B16-
F10 cells. Tumors were allowed to grow for 7 to 10 days to a volume
of 40 to 50 mm3 before treatment.
Plasmid. pUCMV3-mIL-12 (Aldevron, Fargo, ND), containing the
murine p35 and p40 IL-12 cDNAs under the control of the
cytomegalovirus promoter, was prepared by the manufacturer. Endo-
toxin levels were <100 endotoxin units/mg. Before use, plasmid DNA
was diluted in 0.9% sterile injectable saline to the appropriate
concentration for each experiment.
Tumor treatment. Treatments were done on days 1, 5, and 8 after
tumor growth. Briefly, mice were initially anesthetized in an induction
chamber that was infused with a mixture of 3% isoflurane and 97%
O2 for several minutes then fitted with a standard rodent mask
supplied with 2% isoflurane in O2. Group 1 animals received only an
intratumor 0.05 mL saline injection. Group 2 animals received an
intratumor injection of 0.05 mL 0.1 mg/mL pUCMV3-mIL-12 only. In
Group 3, injection of 0.05 mL 0.1 mg/mL pUCMV3-mIL-12 was
followed by application of six 0.1 ms pulses with field strength of
1,300 V/cm from a MedPulser Electroporation System (Inovio
Biomedical Corporation, San Diego, CA) delivered using a six needle
array. Group 4 received an intratumor injection of 0.05 mL 1 mg/mL
pUCMV3-mIL-12 only, whereas group 5 received an intratumor
injection of 0.05 mL 1 mg/mL pUCMV3-mIL-12 followed by pulses.
Tumor monitoring. Tumors were monitored every 2 to 3 days; not
all data points were shown. Tumors were monitored using a digital
caliper. Tumor volume was calculated by the standard formula
v = pab2/6, where a is the longest diameter and b is the next longest
diameter perpendicular to a .
Sample collection. Each mouse was monitored for body weight and
general condition on a daily basis beginning the day before the first
treatment. The general condition of the mice included examination of
the coat, demeanor, and health of the animal. The evaluation of
demeanor and health of the mouse was determined by observing if the
mouse was eating, drinking, and moving without discomfort.
On days 9 (the day after the third treatment), 11, 16, 23, and 30 after
treatment, 10 mice from each group (5 male and 5 female) were
euthanatized. Blood was collected from each animal in heparinized
tubes, and tissue samples taken in order: brain, spleen, kidney, liver,
lung, heart, lymph nodes, then finally tumor, and skin around the
tumor. Different sets of instruments were used to avoid cross-
contamination.
Histologic analysis. Tissue samples from groups 1, 4, and 5 on days
9, 16, and 30 were blinded and analyzed histologically. Each specimen
obtained for analysis was submitted entirely for histologic examination.
Radial and sagittal sections were taken. After fixation, sections were
stained with H&E (Richard-Allan Scientific, Kalamazoo, MI) using
standard histologic techniques.
Results
Treatments were done on days 1, 5, and 8 after tumor growth
(see Materials and Methods). Group 1 animals received only an
intratumor 0.05 mL saline injection. Group 2 animals received
a low-dose (0.005 mg pUCMV3-mIL-12) intratumor injection
only. In group 3 animals, a low-dose intratumor plasmid
injection was followed by application of pulses as described.
Group 4 received a high-dose (0.05 mg pUCMV3-mIL-12)
Fig. 1. Tumor growth in females (A) and males (B). o, group1; D, group 2;E, group 3;r, group 4; 5, group 5. Error bars, standard deviation of the mean.
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intratumor injection only, whereas group 5 received a high-
dose intratumor plasmid injection followed by pulses.
General health status and survival. No significant weight
loss was observed in any of the treatment groups when
compared with the group that received saline injection alone
(group 1). Five of the group 1 males, two of the group 1
females, and one group 4 male did not survive to the final time
point due to unimpeded tumor growth. Overall, mice seemed
to have a generally healthy appearance with the exception of
the tumor growth.
Tumor growth or regression. Tumor growth in most male
groups and in all female treated groups was significantly
delayed when compared with group 1 (Fig. 1). Tumors
continued to grow in group 1 mice with no objective or
complete responses observed. In males, all treated groups
showed a significant reduction in tumor growth from day 13 to
23, with the exception of group 4, which showed no significant
difference from group 1 during this time period. In females, all
treated groups showed a significant reduction in tumor growth
from day 11 to 23. Day 30 (the final day tested) was
significantly different in group 5 only. This pronounced
reduction in tumor volume included a large percentage of
complete regressions, particularly at the later time points.
The regression status of all mice was observed at the time
points the mice were euthanatized for toxicity studies (Fig. 2).
Complete regressions were observed in males in groups 3 and 5,
whereas complete regression was observed in females in groups
3, 4, and 5. All deaths before euthanasia were due to disease
progression. Metastatic disease was observed on necropsy in six
males (groups 1 and 4) and two females (group 1).
Chemistry and hematology findings. Blood chemistry and
hematology values were established in 10 male and 10 female
naive, healthy mice (Tables 1 and 2). At 9, 11, 16, 23, and 30
days after the initial plasmid delivery, whole blood from five
males and five females in each group was tested and compared
with the established normal values.
Table 1. Complete blood count values for normal,
healthy mice
Females Males
Mean SD Mean SD
WBC 4.72 2.03 6.19 2.15
%Neutrophils 10.11 2.99 21.01 12.36
%Leukocytes 84.37 4.29 70.52 15.48
%Macrophages 4.31 1.4 6.81 3.26
%Eosinophils 0.1 0.15 0.09 0.05
%Basophils 1.11 0.56 1.58 0.65
RBC 8.6 0.66 9.34 0.57
Hemoglobin 13.6 1.17 14.42 0.97
Hematocrit 40.74 3.31 43.81 3.13
MCV 189.2 2.54 187.64 3.36
MCH 63.24 1.35 61.72 1.08
MCHC 133.64 2.01 131.56 1.71
RDW 56.16 3 57.32 4.06
Platelets 1035.6 115.85 1342.8 119.9
MPV 18.63 0.39 18.88 0.5
Pack crit 0.48 0.05 0.63 0.05
PDW 62.64 1 62.84 0.79
Abbreviations: MCV, mean corpuscular volume; PDW, platelet distribution
width.
Fig. 2. Response rates. Columns,
percentage of mice that had an objective
response (A and B) or complete response
(C and D).There were five mice at each
time point for each group, except for
group1on day 30 (zero male and three
female survivors) and group 4 on day 30
(four male and five female survivors).
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Group 1 mice showed an increased number of atypical
hematology values when compared with normal naive
controls, although blood chemistry values were not more
likely to be atypical than in the treated groups. Statistically
significant differences (P < 0.01) were observed sporadically in
most of 17 standard hematology categories (Table 3). Male
values tended to be significantly decreased or increased more
often than female values. In both males and females, group 1
mice displayed increasingly aberrant values with time. In
males, RBCs, hemoglobin, and hematocrit in particular were
reduced at later time points. In females, hemoglobin and
hematocrit were reduced, whereas an increased mean platelet
volume (MPV) was observed at later time points. Females in
groups 2, 3, and 4 did not show trends in significantly different
values, whereas females in group 5 showed a decreased mean
corpuscular hemoglobin (MCH) concentration (MCHC) over
time. Males in group 2 tended to have an increased RBC
distribution width (RDW). Males in group 3 showed increased
RBCs and hemoglobin only at the early time points. Group 4
males showed decreased RBCs, hemoglobin, and hematocrits
at later time points. Untreated mice showed progressive
lymphocytopenia, anemia, and neutrophilia. These changes
were seen but to a lesser extent in the injection-only groups. No
significant abnormalities were seen in the high-dose electro-
poration group. These results suggest that the combination of
plasmid injection and electroporation was not associated with
bone marrow suppression.
In female untreated mice, progressive azotemia and hypo-
albuminemia was seen with progressive melanoma (Table 4).
These changes were observed also in the injection-only group of
females but not in females that received high dose of plasmid
and electroporation. In the male mice, these abnormalities were
Table 2. Mean blood chemistry for normal, healthy mice
Glucose BUN Creatinine Albumin Total
bilirubin
Alkaline
phosphatase
Aspartate
aminotransferase
Alanine
aminotransferase
Females
Mean 209.6 16.2 0.26 2.08 0.16 154.4 186.9 44.4
SD 40.58 1.75 0.07 0.13 0.11 12.95 96.33 12.29
Males
Mean 253.6 16.5 0.22 1.91 0.1 111.5 121.1 34.5
SD 23.64 1.96 0.04 0.19 0 25.95 40.72 8.7
Table 3. Complete blood count values differing from mean of normal, healthy mice (P < 0.01)
Group Day 9 Day11 Day16
Increased Decreased Increased Decreased Increased Decreased
Females
I None MCV %B Hemoglobin %M,MPV %L, RBC, hemoglobin,
hematocrit
II MCHC MCV None MCH,MCHC None None
III Platelets, pack crit MCV None MCH,MCHC MPV, pack crit None
IV MPV None MPV MCHC MPV None
V %E MCV MPV MCHC None MCH,
MCHC
Males
I MCV None %B,MCV MCHC, PDW, RBC,
hemoglobin, hematocrit
%E RBC, hemoglobin,
hematocrit
II %E None Pack crit None %E, %B,
RDW
None
III RBC, hemoglobin,
hematocrit,
platelets,
pack crit
None RBC, hemoglobin,
hematocrit, platelets,
pack crit
None RBC, hemoglobin,
platelets, pack crit
MCV
IV %B, RBC,
hemoglobin,
hematocrit, platelets,
pack crit
None None None MCHC Hematocrit
V None WBC,
MCHC
None None MCHC None
Cancer Therapy: Preclinical
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seen, and, in addition, hypoglycemia was also observed in the
untreated males. In males that received injection of plasmid
and electroporation, these changes were also observed but to a
lesser extent.
Serum was also assayed for levels of IL-12 following each
treatment. No significant serum IL-12 levels were seen in any
group (data not shown).
Histopathology. In general, the untreated animals comprised
the most profound histopathologic abnormalities. The predom-
inant tissue that showed metastatic spread was the skin around
the tumor. Tumor growth in the skin was found in 31% of group
1 mice, whereas only 12% of group 4 mice and 8% of group 5
mice were positive. It should be noted that the tumor growth in
the skin observed in group 5 mice occurred predominately at an
early time point (day 9). Metastatic spread was also particularly
observed to the lymph nodes and liver in groups 1 (12% to both
tissues) and 4 mice (17% lymph nodes and 12% liver). Lymph
nodes (4%) and liver (2%) involvement was greatly decreased in
group 5 mice, although, in one mouse in this group, kidney and
spleen metastases were observed. No metastases were observed
in the lungs, heart, or brain in any group. In addition, acute and
chronic inflammation in the skin around the tumor was
observed particularly in groups 1 (12% to in both tissues) and
4 (17% in lymph nodes and 12% in liver).
No abnormalities were seen in brain or heart tissue. Lungs
were congested, and focal acute and chronic inflammation was
observed in all mice. Most mice showed extramedullary
hematopoiesis, which is a common and normal phenomenon
in the spleen of C57Bl/6 mice (29). Focal inflammation in the
kidney was not observed in group 1 females but was observed
in two of five group 4 females by day 16 and one of five by day
30. Two of five group 5 females also showed focal inflamma-
tion in the kidney at day 16, and the level of inflammation
increased to four of five by day 30. In males, kidneys in groups
1 and 4 males were normal, but three of five of the group 5
males showed focal glomerulosclerosis at the later time points.
Discussion
IL-12 is a cytokine that shows promise as an anticancer agent.
In human phase I clinical trials, systemic infusions of
recombinant IL-12 protein were toxic but showed clinical
activity. Since then, multiple investigators have shown that, in
animal models, direct delivery of IL-12 to the tumor site
maintains its anticancer activity but avoids much of the toxic
side effects (4, 26, 30). Recent phase I melanoma clinical trials
using localized IL-12 gene therapy alone have reported local
production of IL-12 via injection of naked plasmid DNA (5) or
of IL-12 producing transduced autologous cells (31, 32). Recent
preclinical data suggest that the efficacy of IL-12 gene therapy
can be dramatically increased by electrically mediated gene
transfer (22, 21).
Pulsed electric fields (electroporation) are effective means of
enhancing intracellular delivery of molecules in vivo . Electro-
chemotherapy, which combines an antitumor drug with
electroporation, is an effective localized treatment for a variety
Table 3. Complete blood count values differing from mean of normal, healthy mice (P < 0.01) (Cont’d)
Day 23 Day 30 Total, n (%)
Increased Decreased Increased Decreased
%N,
%M,MCH,
MCHC,
RDW,MPV
%L, RBC,
hemoglobin,
hematocrit,
platelets,
pack crit
WBC, %N, %M, %B,
RDW,MPV,
pack crit, PDW
%L, hemoglobin,
hematocrit,
MCV,MCH
21/68 (30.9)
None RBC, hemoglobin %N, RDW,MPV %L, RBC, hemoglobin,
hematocrit
13/85 (15.3)
None RBC WBC, %N, %B, platelets,
pack crit
%L 14/85 (16.5)
None RBC, hemoglobin,
hematocrit
None RBC, hemoglobin,
hematocrit
10/85 (11.8)
None MCH,MCHC None %M,MCH 10/85 (11.8)
%N,MCV,
RDW,MPV
%L, RBC,
hemoglobin,
hematocrit,
platelets
34/85 (40)
%E, MCH,
RDW
RBC, hemoglobin,
hematocrit
WBC, %N, RDW,MPV %L, RBC, hemoglobin,
hematocrit
19/85 (15.3)
%E None %E MCH 18/85 (21.2)
%N, %E, %B,
MCV,
platelets,
MPV, PDW
%L, RBC,
hemoglobin,
hematocrit,
RDW, pack crit
%N, %M, platelets,
MPV, PDW
%L, RBC, hemoglobin,
hematocrit,
RDW, pack crit
32/85 (37.6)
None MCHC RBC, hematocrit MCH 7/85 (8.2)
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of tumor types (33). This electrically enhanced drug delivery
has progressed to several successful clinical trials (34, 35).
Because electroporation is a physical method that facilitates
uptake of molecules by increasing the permeability of the cell
membrane, it can be used to effectively deliver a variety of
molecules to a broad range of cell types. The main limitation to
in vivo electroporation is the ability to access the tissue to inject
the molecule to be delivered and properly place the electrodes.
Although electric fields have been used to deliver chemotherapy
(electrochemotherapy) to s.c. tumors, they have not been used
to introduce DNA constructs in humans. The use of electric
pulses for the in vivo delivery of genes is in an earlier stage of
development.
Several studies have indicated that gene delivery could
potentially achieve a similar success as drug delivery (30).
Studies accomplished thus far have shown that in vivo
electroporation could enhance the delivery of plasmid DNA
to several tissue types. Of interest is the ability to control the
expression levels and kinetics of expression by carefully
choosing the electroporation variables (30, 36).
The electroporation conditions (field strength, pulse dura-
tion, and electrodes) proposed to be used for the IL-12
electrogene transfer study are essentially the same as those
used in the electrochemotherapy clinical studies. These
conditions were well tolerated in the electrochemotherapy
trials. Although electrochemotherapy has had tremendous
success in inducing tumor regression, this effect was localized
to the treated lesion. Therefore, the effect could be even higher
for gene delivery, as this therapy could potentially elicit
systemic effects. Results presented in this report as well as in
previous studies have shown the potential of this delivery
system as part of an antitumor regimen. Work in the B16-F10
model produced strong evidence of this potential. Complete
long-term responses can be obtained following treatment of
established melanoma tumors using this system to deliver a
plasmid encoding IL-12. The majority of mice that had durable
long-term regressions were also resistant to challenge (21, 22).
In addition, intramuscular delivery produced high serum
cytokine levels, which prevented the formation of lung lesions
following tail vein injection of B16-F10 cells (22).
Although the potential efficacy of this approach has been
shown in preclinical animal studies, it was necessary to evaluate
potential toxicity of this approach to translate this delivery
approach to the clinic. Although a previous study showed that
there was minimal toxicity associated with direct delivery
(intratumor injection of plasmid) of IL-12 plasmid in the B16
mouse melanoma model (4), electrically mediated delivery had
not been evaluated. Therefore, this study was designed to assess
toxicity associated with this therapeutic approach. The results of
this study showed that there was no significant toxicity
associated with the electrically mediated delivery of a plasmid
encoding IL-12. The only abnormality specific to animals
receiving both plasmid and electroporation was inflammation
associated with the kidney at the late time point. We did
not, however, observe creatinine elevation in these mice. In
human renal disease, focal glomerulosclerosis can manifest
with asymptomatic proteinuria or edema (37). Therefore, we
would recommend monitoring of renal function in human
Table 4. Blood chemistry values differing from mean of normal, healthy mice (P < 0.01)
Group Day 9 Day11 Day16 Day 23 Day 30 Total (%)
Inc Dec Inc Dec Inc Dec Inc Dec Inc Dec
Females
I BUN None None ALKP,
ALT
BUN ALKP BUN Albumin,
ALKP
BUN ALKP 10/40 (25)
II BUN None None None None None BUN Albumin,
ALKP
BUN Albumin,
ALKP
7/40 (17.5)
III BUN None None None BUN None BUN None None ALKP,
ALT
5/40 (12.5)
IV None None BUN None None None BUN None BUN ALKP 4/40 (10)
V None None BUN,
ALKP
None ALKP None BUN,
ALKP
Glucose None None 6/40 (15)
Males
I None None AST None AST Glucose,
ALKP
BUN, AST Glucose,
ALKP
8/32 (25)
II None None BUN Glucose AST Glucose,
ALKP
AST Glucose,
ALKP
AST Glucose,
ALKP
11/40 (27.5)
III BUN,
ALT
Glucose None Glucose BUN Glucose AST Glucose,
ALKP
AST Glucose,
ALKP
12/40 (30)
IV None None BUN None BUN ALKP AST Glucose,
ALKP
AST ALKP,
glucose,
Albumin
10/40 (25)
V None None None None None Glucose None None BUN Glucose 3/40 (7.5)
Abbreviations: Inc, increased; Dec, decreased; ALKP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase.
Cancer Therapy: Preclinical
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IL-12/electroporation trials and should include monitoring of
blood urea nitrogen (BUN)/creatinine, urine sediment, and
hypotension. It should also be pointed out that, in general,
these mice showed the least abnormal histopathologic findings
and were found to be in the best health, which, we believe,
reflects a reduced burden of disease.
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